| Mr Richard D Blevins, MD | |
|
1101 26th St S, Great Falls, MT 59405-5161 | |
| (406) 731-8888 | |
| (406) 731-8876 |
| Full Name | Mr Richard D Blevins |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 1101 26th St S, Great Falls, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851392740 | NPI | - | NPPES |
| 1851392740 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 4766 (Montana) | Secondary |
| 208M00000X | Hospitalist | 4766 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Richard D Blevins, MD 1101 26th St S, Great Falls, MT 59405-5161 Ph: (406) 731-8888 | Mr Richard D Blevins, MD 1101 26th St S, Great Falls, MT 59405-5161 Ph: (406) 731-8888 |
News Archive
Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease.
During her opening address to the World Health Assembly in Geneva, Switzerland, on Monday, WHO Director-General Margaret Chan called for increased global efforts to reach the Millennium Development Goals, PANA/Afrique en ligne reports. Chan also set-up several global health challenges to be addressed during the five-day meeting, according to the news service.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
› Verified 7 days ago
Elias J. Baied, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1401 25th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8318 | |
Chu Shei Hong, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-455-5319 Fax: 406-455-4173 | |
Dr. James Tennent Geren, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8876 | |
Dr. Michael Shun Yeen Yu, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8318 | |
Mr. Don Stuart Wipf, FNP-BC Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1609 41st St S, Great Falls, MT 59405 Phone: 605-360-8477 | |
Tauqeer Rahat, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 443-851-6886 | |
Mrs. Teresa Frey, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8318 |